Estimate kidney transplant graft survival using HLA mismatch, donor age, cold ischemia time, PRA, and sensitization status.
Kidney transplantation is the optimal treatment for end-stage renal disease, offering superior survival and quality of life compared to dialysis. However, transplant outcomes vary substantially based on immunologic compatibility, donor quality, and recipient factors. HLA matching remains the cornerstone of immunologic risk assessment — each additional mismatch at HLA-A, B, and particularly DR loci incrementally increases the risk of acute and chronic rejection.
Panel reactive antibodies (PRA) quantify the sensitization burden — the percentage of potential donors against whom the recipient has preformed antibodies. Highly sensitized patients (PRA > 80%) face prolonged waitlist times and higher rejection risk. Cold ischemia time — the duration between organ procurement and reperfusion — directly impacts delayed graft function risk, with each hour beyond 12 hours incrementally worsening outcomes.
This calculator integrates recipient age, donor age, HLA mismatch, cold ischemia time, PRA, sensitization history, donor type, and retransplant status to provide composite risk stratification with estimated 1-, 5-, and 10-year graft survival probabilities, projected graft half-life, and immunosuppression intensity recommendations.
Transplant recipients and teams need clear communication about expected outcomes based on specific donor-recipient characteristics. This calculator provides individualized risk assessment, survival projections, and immunosuppression intensity guidance to help inform informed consent discussions and pre-transplant planning. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain. Use this clarification to avoid ambiguous interpretation.
Risk score = recipient age points + donor age points + (HLA-DR MM × 3) + (HLA-B MM × 2) + (HLA-A MM × 1) + cold ischemia points + PRA points + sensitization bonus + deceased donor points + DCD points + retransplant points. Living donor bonus applied to survival estimates.
Result: Standard risk, 1-year graft ~ 94%, 5-year ~ 82%, 10-year ~ 65%
A 52-year-old recipient receiving a kidney from a 38-year-old deceased donor with 1 HLA-A mismatch, PRA 25%, and 14 hours cold ischemia falls into standard risk with good expected outcomes.
The human leukocyte antigen (HLA) system is encoded on chromosome 6 and consists of Class I (HLA-A, B, C) and Class II (HLA-DR, DQ, DP) antigens. Each person inherits one haplotype from each parent, giving two alleles at each locus. In kidney transplantation, matching is conventionally assessed at HLA-A, B, and DR (6 potential mismatches). Zero-mismatch transplants have the best outcomes and receive priority in deceased donor allocation. The emerging importance of HLA-DQ and HLA-C mismatches is increasingly recognized, with some programs now incorporating these into risk assessment.
The KDPI quantifies deceased donor kidney quality on a percentile scale (0-100%) based on donor age, height, weight, ethnicity, hypertension, diabetes, cause of death, serum creatinine, HCV status, and DCD status. A KDPI of 20% means the kidney is expected to have longer function than 80% of deceased donor kidneys. KDPI helps inform organ acceptance decisions — younger recipients with low PRA may benefit from waiting for a lower KDPI organ, while older recipients or those on prolonged dialysis may benefit from accepting a higher KDPI organ sooner.
Modern immunosuppression has dramatically reduced acute rejection rates to < 10% in the first year. Induction therapy (basiliximab or ATG) depletes or blocks T-cell activation at the time of transplant. Maintenance therapy typically combines tacrolimus + mycophenolate ± steroids. Belatacept offers a calcineurin inhibitor-free approach for suitable patients. The challenge has shifted from preventing acute rejection to managing chronic antibody-mediated rejection, which remains the leading cause of late graft loss.
HLA-DR antigens are expressed on antigen-presenting cells and directly activate CD4+ T helper cells, which orchestrate the adaptive immune response against the graft. DR mismatches generate the strongest immune response and have the most significant impact on both acute rejection episodes and long-term graft survival. A single DR mismatch is roughly equivalent to two HLA-A or HLA-B mismatches in terms of immunologic risk.
Cold ischemia time (CIT) is the duration from when the donor organ is flushed with preservation solution and cooled until blood flow is restored in the recipient. During this period, ischemia-reperfusion injury occurs. CIT > 24 hours significantly increases delayed graft function (DGF) risk, which in turn increases acute rejection and chronic graft loss. Living donor kidneys have minimal CIT (usually < 2 hours), contributing to their superior outcomes.
PRA measures the percentage of a panel of donor lymphocytes that react with the recipient's serum. A PRA of 50% means the recipient has antibodies against 50% of potential donors. High PRA results from prior sensitization events: blood transfusions, pregnancies, or prior transplants. Highly sensitized patients (PRA > 80%) qualify for priority allocation under UNOS but still face higher rejection risk even with a crossmatch-negative donor.
Living donor kidneys have 3-5 year longer graft half-lives compared to deceased donor kidneys. This is due to several factors: minimal cold ischemia time (usually < 2 hours versus 12-24+ hours), ability to thoroughly evaluate donor health, scheduling the transplant when the recipient is optimally prepared, and typically younger/healthier donor demographics. The 10-year graft survival for living donor kidneys approaches 80% versus 55-65% for deceased donors.
DBD (donation after brain death) is the traditional deceased donor pathway where brain death is declared before organ procurement. DCD (donation after circulatory death) involves organ procurement after withdrawal of life-sustaining treatment and circulatory arrest. DCD kidneys experience a period of warm ischemia before procurement, which increases delayed graft function risk. However, long-term outcomes of DCD kidneys are approaching those of DBD kidneys in experienced centers.
Absolutely. Even highly sensitized patients (PRA > 80%) derive survival benefit from transplantation versus remaining on dialysis. Modern desensitization protocols (plasmapheresis, IVIg, rituximab, bortezomib) can make transplantation possible across positive crossmatches. Paired kidney exchange programs and the UNOS priority allocation for sensitized patients have shortened waitlist times. Virtual crossmatch technology has improved pre-transplant antibody assessment.